Funding for dedicated photonics pilot-line for medical diagnostics at VTT
Photonics enables various medical applications from diagnostic devices to instruments for treatment. However, both photonics and its areas of application are fragmented, which poses challenges to equipment manufacturers. Furthermore, the strict regulations within the sector slow down the introduction of new solutions. The project addresses these issues to accelerate the commercialisation of diagnostic devices and instruments for treatment based on photonics, and to reduce the R&D costs. The orders for the MedPhab pilot production line are made in a centralised manner and channelled to the manufacturer with the best implementation capability.
The pilot production line focuses on three application areas intended for hospital use, home care devices and equipment for chemical diagnostics.
In a hospital environment, the solutions assist doctors by giving them real-time information of how the treatment is progressing, without the need to send patient samples to a laboratory. The equipment for home diagnostics, can be used for monitoring how a patient is recovering from an operation or a fit of illness and for getting a wider picture of the situation than currently possible. Chemical diagnostics is about establishing a clinical picture or diagnosing an infection based on a serum, saliva or urine sample.
The pilot production line is being developed in a consortium involving research institutes and companies from various parts of Europe. The role of research institutes is to develop new production technologies. Use-case companies have been selected for the validation of the pilot line services covering both in-vivo and in-vitro domains next-generation wearable devices using optics.
MedPhab is an initiative of the Photonics Public Private Partnership and connected to Photonics21. The project is coordinated by research professor Jussi Hiltunen, VTT – Technical Research Centre of Finland.